| Category | Details |
| Definition | Glaucoma is a group of eye conditions that damage the optic nerve, often due to abnormally high intraocular pressure (IOP). |
| Global Epidemiology | – Affects ~76 million people globally, projected to increase to 111 million by 2040. |
| – Leading cause of irreversible blindness worldwide. |
| – Strong genetic and age-related risk factors. |
| Prevalence in Key Regions | – United States: ~4.22 million affected; second leading cause of blindness. |
| – European Union: Estimated ~8 million cases; prevalence higher in Southern Europe. |
| – India: ~12 million cases; major public health concern due to late diagnosis. |
| – China: ~21 million affected, with significant challenges in early detection and treatment. |
| – Caribbean: Estimated ~300,000 cases, with limited access to advanced treatments. |
| Medicinal Cannabis Approvals | – United States (FDA): No cannabis products specifically approved for glaucoma; THC studied for IOP reduction. |
| – Canada: Cannabis authorized for chronic conditions; used off-label for glaucoma symptom management. |
| – European Union (EMA): Limited approvals; cannabinoids in clinical trials for IOP reduction. |
| – Australia (TGA): Approved CBD for neurological disorders; off-label use for glaucoma common. |
| – Israel: Medical cannabis approved for conditions involving IOP management since 2013. |
| Therapeutic Cannabinoids | – THC (Tetrahydrocannabinol): Shown to reduce intraocular pressure (IOP) temporarily; psychoactive effects limit its use. |
| – CBD (Cannabidiol): Anti-inflammatory properties; may counteract THC’s IOP-reducing effects. |
| – CBG (Cannabigerol): Emerging evidence for IOP reduction and neuroprotection. |
| Mechanism of Action | – THC: Reduces IOP by modulating CB1 receptors in the ciliary body, enhancing aqueous humor outflow. |
| – CBG: Enhances trabecular meshwork function and reduces oxidative stress in ocular tissues. |
| Key Clinical Studies | – Hepler and Frank, 1971: First study demonstrating IOP reduction with cannabis in glaucoma patients. |
| – Tomida et al., 2006: THC reduced IOP in glaucoma patients; effects lasted ~4–6 hours. |
| – Nucci et al., 2020: Suggested neuroprotective effects of cannabinoids for optic nerve preservation. |
| Dosage Guidelines | – THC (Oral): Starting dose of 2.5 mg/day for IOP reduction; titration based on tolerance and response. |
| – CBG (Experimental): Early trials suggest 10–20 mg/day may be effective for IOP management. |
| Administration Methods | – Sublingual Oils: Direct absorption ensures faster action for acute IOP reduction. |
| – Oral Capsules: Consistent dosing preferred for long-term management. |
| – Inhalation: Provides rapid onset; not recommended due to psychoactive effects and dosing variability. |
| Adverse Effects | – THC: Common: Dizziness, dry mouth, and euphoria; potential for dependency with long-term use. |
| – CBD: May counteract IOP reduction effects of THC; mild fatigue and diarrhea reported. |
| – CBG: Limited evidence; mild sedation and dry mouth in experimental trials. |
| Research Gaps | – Limited long-term studies on cannabinoids’ safety and efficacy for glaucoma. |
| – Potential interactions between cannabinoids and standard glaucoma treatments remain underexplored. |
| Opportunities in the Caribbean | – High Prevalence: ~300,000 cases with limited access to advanced IOP management and optic nerve preservation therapies. |
| – Cannabis Clinics: Establishing clinics focused on cannabinoid treatments for glaucoma could meet local needs and attract medical tourists. |
| – Research Hub: Developing regional expertise to explore cannabinoid-based therapies for IOP reduction and neuroprotection. |
